Regeneron Q3 revenue $3.36B (+15%); GAAP EPS $8.89, non-GAAP EPS $11.59; EYLEA HD launch begins

REGENERON PHARMACEUTICALS, INC.

2023-Q3 EPS reported $24.57 revenue$9,682,900,000

Revenue $3.363B (+15% YoY); GAAP EPS $8.89, non-GAAP EPS $11.59.
EYLEA HD launched post-FDA approval, generated $43M U.S. net sales in Q3.
Dupixent global net sales (Sanofi) $3.10B (+33% YoY); Libtayo global net sales $232M (+62%).
FDA accepted priority reviews for odronextamab in FL/DLBCL and Dupixent in pediatric EoE; CRL for Dupixent in CSU.
CFO Robert Landry to retire Feb 2024; Christopher Fenimore to succeed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REGENERON PHARMACEUTICALS, INC. reported the quarter ended September 30, 2023 results: revenue $3,363, net income $1,008, EPS $8.89.

Period: the quarter ended September 30, 2023
Revenue: $3,363
Net income: $1,008
EPS: $8.89
Result: reported results

Exact text from the filing

to our portfolio through the recent acquisition of Decibel Therapeutics." Financial Highlights ($ in millions, except per share data) Q3 2023 Q3 2022 % Change Total revenues $ 3,363 $ 2,936 15 % GAAP net income $ 1,008 $ 1,316 (23 %) GAAP net income per share - diluted $ 8.89 $ 11.66 (24 %) Non-GAAP net income (a) $ 1,329 $ 1,270 5 % Non-GAAP net income per

View on SEC.gov

Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001804220-23-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.